Apart from approved antibodies and kinase inhibitors, targeting either growth factor receptor tyrosine kinases (EGFR, PDGFR, VEGFR, c-MET et al.), downstream kinases (BRAF, MEK, AKT, mTOR et al.), or fusion proteins (BCR-ABL) dysregulated in tumors, a number of alternative small-molecule drugs and natural compounds are available for tumor therapy. Here, BRAF is linked to neoplasm.